Expand Access/Assess Safety and Efficacy of Paromomycin IM Injection for the Treatment of Visceral Leishmaniasis
A Phase 4 Study to Expand Access Program While Assessing the Safety and Efficacy of Paromomycin IM Injection in an Outpatient Setting for the Treatment of Visceral Leishmaniasis
Sponsor: PATH
Listed as NCT00604955, this PHASE4 trial focuses on Visceral Leishmaniasis and remains completed. Sponsored by PATH, it has been updated 5 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE4
First recorded
Oct 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- PATH
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Agam Kuan, Patna, India
- • Azad Nagar, Balua Tal, Motihari, India
- • Bengali Tola, Samastipur, India
- • Brahmpura, India
- • East of Bhola Talkies, Samastipur, India
- • Patna, India
- • Rambagh Road, Muzaffarpur, India